Pathos, an AI-driven drug development company, raised a $237 million Series E at a $3 billion valuation led by Bristol Myers Squibb. The funding expands Pathos’s datasets and operational footprint, including a reported push from oncology into neurological conditions. The company plans to leverage new datasets from Tempus AI and work with BMS under a partnership first targeting Alzheimer’s. Pathos markets its Foundry platform as an agent-based system that estimates probability of clinical success and helps guide asset selection, trial population strategy, and trial design. The round underscores how major biopharma players are continuing to fund early-stage AI-native platforms, while also reflecting growing interest in translating model outputs into development execution.